A global leader in diabetic care, Ascensia Diabetes Care, has launched the world’s first FDA-approved continuous glucose monitoring (CGM) system in the United States to improve glucose level management for people living with type 1 and 2 diabetes.
Known as Eversense® 365, the CGM system is the first and only device available that provides continuous year-round glucose monitoring using just a single sensor.
Eversense provides users with real-time glucose monitoring through a tiny sensor implanted under the skin of their upper arm and a transmitter positioned on the arm, just above the sensor. The transmitter feeds data directly into the Eversense app on the user’s smartphone in real time.
Connected to the transmitter via Bluetooth, the Eversense app displays blood glucose values in a graphical representation updated every 5 minutes. Based on these values, users can keep track of their glucose levels and easily know when they are below, above, or within their target range. The app also allows users to share their real-time values with up to 5 people.
Eversense® 365— First Year-long CGM System
Eversense 365 addresses the long-standing challenges associated with traditional glucose monitoring systems, which usually provide shorter-term monitoring of about 10 to 14 days before they are replaced.
The innovative CGM device provides more accurate monitoring with minimal incidences of false alarms, empowering users to take control of their blood sugar and enhancing their quality of life.
